Improved pharmacokinetics and immunogenicity profile of organophosphorus hydrolase by chemical modification with polyethylene glycol

Journal of Controlled Release

Volumn 146, Issue 3, 2010, Pages 318-325

  Novikov, Boris N ^a   Grimsley, Janet K ^a   Kern, Rory J ^a   Wild, James R ^a   Wales, Melinda E ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Immunogenicity; Organophosphorus hydrolase; PEG; PEGylation; Pharmacokinetics

Indexed keywords

ANIMAL STUDIES; BACTERIAL ENZYMES; BLOOD STREAMS; CATALYTIC ACTIVITY; CATALYTIC RATES; GUINEA PIGS; HUMORAL IMMUNE RESPONSE; IMMUNOGENICITY; IN-VIVO; MILITARY RESEARCH; NERVE AGENTS; NEW OPPORTUNITIES; ORGANOPHOSPHORUS HYDROLASE; PARAOXON; PEG; PEGYLATION; PHARMACOKINETIC PROPERTIES; POTENTIAL APPLICATIONS; REDUCED PRODUCTION; RESIDENCE TIME; SUBSTRATE SPECIFICITY; THERMAL STABILITY; THREAT AGENTS; THREAT SCENARIOS;

CHEMICAL MODIFICATION; DETOXIFICATION; ENZYMES; ESTERS; PHARMACOKINETICS; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; SUBSTRATES;

CATALYST ACTIVITY;

ANTIBODY; ARYLDIALKYLPHOSPHATASE; DISULFOTON; MACROGOL; PARAOXON;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; AREA UNDER THE CURVE; ARTICLE; CATALYSIS; CHEMICAL MODIFICATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG HALF LIFE; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME SPECIFICITY; GUINEA PIG; HUMORAL IMMUNITY; IMMUNOGENICITY; MALE; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ANALYSIS; THERMOSTABILITY;

ANIMALS; ANTIBODIES; ARYLDIALKYLPHOSPHATASE; GUINEA PIGS; MALE; MODELS, MOLECULAR; POLYETHYLENE GLYCOLS; PROTEIN CONFORMATION;

EID: 77956289645     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.06.003     Document Type: Article

References (43)

1. Singh B.K., Walker A. Microbial degradation of organophosphorus compounds. FEMS Microbiol. Rev. 2006, 30:428-471.
2. Reeves T.E., Wales M.E., Grimsley J.K., Li P., Cerasoli D.M., Wild J.R. Balancing the stability and the catalytic specificities of OP hydrolases with enhanced V-agent activities. Protein Eng. Des. Sel. 2008, 21:405-412.
3. McDaniel C.S., McDaniel J., Wales M.E., Wild J.R. Enzyme-based additives for paints and coatings. Prog. Org. Coat. 2006, 55:182-188.
4. Simonian A.L., diSioudi B.D., Wild J.R. An enzyme based biosensor for the direct determination of diisopropyl fluorophosphate. Anal. Chim. Acta 1999, 389:189-196.
5. Viveros L., Paliwal S., McCrae D., Wild J., Simonian A. A fluorescence-based biosensor for the detection of organophosphate pesticides and chemical warfare agents. Sens. Actuators B Chem. 2006, 115:150-157.
6. Gallo B.J., Lawryk N.J. Organic phosphorus pesticides. Handbook of Pesticide Toxicology 1991, 917-983. Academic Press, Inc., San Diego, CA. W.J. Hayes, E.R. Laws (Eds.).
7. Roberts D.M., Aaron C.K. Management of acute organophosphorus pesticide poisoning. BMJ 2007, 334:629-634.
8. Tuovinen K., Kaliste-Korhonen E., Raushel F.M., Hänninen O. Phosphotriesterase - a promising candidate for use in detoxification of organophosphates. Fundam. Appl. Toxicol. 1994, 23:578-584.
9. Petrikovics I., Wales M.E., Jaszberenyi J.C., Budai M., Baskin S.I., Szilasi M., Logue B.A., Chapela P., Wild J.R. Enzyme-based intravascular defense against organophosphorus neurotoxins: synergism of dendritic-enzyme complexes with 2-PAM and atropine. Nanotoxicology 2007, 1:85-92.
10. Abuchowski A., McCoy J.R., Palczuk N.C., van Es T., Davis F.F. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem. 1977, 252:3582-3586.
11. Veronese F.M., Pasut G. PEGylation: posttranslational bioengineering of protein biotherapeutics. Drug Discov. Today Technol. 2008, 5:e57-e64.
12. Fishburn C.S. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J. Pharm. Sci. 2008, 97:4167-4183.
13. diSioudi B., Grimsley J.K., Lai K., Wild J.R. Modification of near active site residues in organophosphorus hydrolase reduces metal stoichiometry and alters substrate specificity. Biochemistry 1999, 38:2866-2872.
14. Grimsley J.K., Scholtz J.M., Pace C.N., Wild J.R. Organophosphorus hydrolase is a remarkably stable enzyme that unfolds through a homodimeric intermediate. Biochemistry 1997, 36:14366-14374.
15. Sainsbury E.J., Ashley J.J. Curve-fitting in pharmacokinetics - a comparison between gamma-and biexponential fits. Eur. J. Clin. Pharmacol. 1986, 30:243-244.
16. Pasut G., Veronese F.M. PEG conjugates in clinical development or use as anticancer agents: an overview. Adv. Drug Deliv. Rev. 2009, 61:1177-1188.
17. Sherman M.R., Saifer M.G.P., Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv. Drug Deliv. Rev. 2008, 60:59-68.
18. Chevaliez S., Pawlotsky J.M. Interferon-based therapy of hepatitis C. Adv. Drug Deliv. Rev. 2007, 59:1222-1241.
19. Webster R., Didier E., Harris P., Siegel N., Stadler J., Tilbury L., Smith D. PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab. Dispos. 2007, 35:9-16.
20. An Q., Lei Y., Jia N., Zhang X., Bai Y., Yi J., Chen R., Xia A., Yang J., Wei S., Cheng X., Fan A., Mu S., Xu Z. Effect of site-directed PEGylation of trichosanthin on its biological activity, immunogenicity, and pharmacokinetics. Biomol. Eng. 2007, 24:643-649.
21. Rosendahl M.S., Doherty D.H., Smith D.J., Carlson S.J., Chlipala E.A., Cox G.N. A long-acting, highly potent interferon a-2 conjugate created using site-specific PEGylation. Bioconjug. Chem. 2005, 16:200-207.
22. Cox G.N., Rosendahl M.S., Chlipala E.A., Smith D.J., Carlson S.J., Doherty D.H. A long-acting mono-PEGylated human growth hormone analog is a potent stimulator of weight gain and bone growth in hypophysectomized rats. Endocrinology 2007, 148:1590-1597.
23. Webster R., Xie R., Didier E., Finn R., Finnessy J., Edgington A., Walker D. PEGylation of somatropin (recombinant human growth hormone): impact on its clearance in humans. Xenobiotica 2008, 38:1340-1351.
24. Tuesca A., Reiff C., Joseph J., Lowman A. Synthesis, characterization and in vivo efficacy of PEGylated insulin for oral delivery with complexation hydrogels. Pharm. Res. 2009, 26:727-739.
25. Park J.B., Kwon Y.M., Lee T.Y., Brim R., Ko M.C., Sunahara R.K., Woods J.H., Yang V.C. PEGylation of bacterial cocaine esterase for protection against protease digestion and immunogenicity. J. Control. Release 2010, 142:174-179.
26. Ryan S.M., Wang X., Mantovani G., Sayers C.T., Haddleton D.M., Brayden D.J. Conjugation of salmon calcitonin to a combed-shaped end functionalized poly(poly(ethylene glycol) methyl ether methacrylate) yields a bioactive stable conjugate. J. Control. Release 2009, 135:51-59.
27. Kronman C., Cohen O., Raveh L., Mazor O., Ordentlich A., Shafferman A. Polyethylene-glycol conjugated recombinant human acetylcholinesterase serves as an efficacious bioscavenger against soman intoxication. Toxicology 2007, 233:40-46.
28. Gaberc-Porekar V., Zore I., Podobnik B., Menart V. Obstacles and pitfalls in the PEGylation of therapeutic proteins. Curr. Opin. Drug Discov. Dev. 2008, 11:242-250.
29. Bailon P., Palleroni A., Schaffer C.A., Spence C.L., Fung W.J., Porter J.E., Ehrlich G.K., Pan W., Xu Z.X., Modi M.W., Farid A., Berthold W., Graves M. Rational design of a potent, long-lasting form of interferon: a 40kDa branched polyethylene glycol-conjugated interferon a-2a for the treatment of hepatitis c. Bioconjug. Chem. 2001, 12:195-202.
30. Kubetzko S., Sarkar C.A., Pluckthun A. Protein PEGylation decreases observed target association rates via a dual blocking mechanism. Mol. Pharmacol. 2005, 68:1439-1454.
31. Caccia D., Ronda L., Frassi R., Perrella M., Del Favero E., Bruno S., Pioselli B., Abbruzzetti S., Viappiani C., Mozzarelli A. PEGylation promotes hemoglobin tetramer dissociation. Bioconjug. Chem. 2009, 20:1356-1366.
32. Davis F.F., Kazo G.M., Nucci M.L., Abuchowski A. Reduction of immunogenicity and extension of circulating half-life of peptides and proteins. Peptide and Protein Drug Delivery 1991, 831-864. Mercel Dekker, New York. V.H.L. Lee (Ed.).
33. Knauf M.J., Bell D.P., Hirtzer P., Luo Z.P., Young J.D., Katre N.V. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. J. Biol. Chem. 1988, 263:15064-15070.
34. Dhalluin C., Ross A., Leuthold L.A., Foser S., Gsell B., Muller F., Senn H. Structural and biophysical characterization of the 40kDa PEG-interferon-alpha2a and its individual positional isomers. Bioconjug. Chem. 2005, 16:504-517.
35. Lu Y., Harding S., Turner A., Smith B., Athwal D.S., Grossmann J.G., Davis K.G., Rowe A.J. Effect of PEGylation on the solution conformation of antibody fragments. J. Pharm. Sci. 2008, 97:2062-2079.
36. Fee C.J. Size comparison between proteins PEGylated with branched and linear poly(ethylen glycol) molecules. Biotechnol. Bioeng. 2007, 98:725-731.
37. Grace M.J., Lee S., Bradshaw S., Chapman J., Spond J., Cox S., DeLorenzo M., Brassard D., Wylie D., Cannon-Carlson S., Cullen C., Indelicato S., Voloch M., Bordens R. Site of PEGylation and polyethylene glycol molecule size attenuate interferon-a antiviral and antiproliferative activities through the JAK/STAT signaling pathway. J. Biol. Chem. 2005, 280:6327-6336.
38. Yang K., Basu A., Wang M., Chintala R., Hsieh M.C., Liu S., Hua J., Zhang Z., Zhou J., Li M., Phyu H., Petti G., Mendez M., Janjua H., Peng P., Longley C., Borowski V., Mehlig M., Filpula D. Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation. Protein Eng. Des. Sel. 2003, 16:761-770.
39. Veronese F.M., Caliceti P., Schiavon O. Branched and linear poly(ethylene glycol): influence of the polymer structure on enzymological, pharmacokinetic, and immunological properties of protein conjugates. J. Bioact. Compat. Polym. 1997, 12:196-207.
40. Zhai Y., Zhao Y., Lei J., Su Z., Ma G. Enhanced circulation half-life of site-specific PEGylated rhG-CSF: optimization of PEG molecular weight. J. Biotechnol. 2009, 142:259-266.
41. Chirino A.J., Ary M.L., Marshall S.A. Minimizing the immunogenicity of protein therapeutics. Drug Discov. Today 2004, 9:82-90.
42. Salmaso S., Semenzato A., Bersania S., Chinol M., Paganelli G., Caliceti P. Preparation and characterization of active site protected poly(ethylene glycol)-avidin bioconjugates. Biochim. Biophys. Acta 2005, 1726:57-66.
43. Edwards C.K. PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases. Ann. Rheum. Dis. 1999, 58:i73-i81.